Researchers have debunked key beliefs about addiction, like that a person must hit "rock bottom" before having treatment or ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The vast majority of people who have a substance use disorder (SUD) never seek treatment. At most, 10% of adults with a drug ...

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid ...

And then, I think one point I definitely want to mention is also the implication that both schizophrenia and substance use disorders increase the risk of developing medical comorbidities." ...

The use of stigmatizing terminology in National Institute on Drug Abuse (NIDA)-funded grant abstracts has decreased by over ...

Across 21 countries, proportion of 12-month person-disorders receiving effective treatment was 6.9 percent. (HealthDay News) — A small number of individuals with mental and substance use disorders ...

"Love Is Blind" contestant Devin Buckley admits to being addicted to ibuprofen. But is that possible? Here, MDs explain ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Nicholas Kristof is right to call for more treatment and prevention. However, by suggesting that drug decriminalization was ...